Business Wire

NY-IMPACTWAYV

15.6.2021 15:02:07 CEST | Business Wire | Press release

Share
ImpactWayv™ Launches Social Media Platform Focused on Social Good

ImpactWayv, Inc. today announced the public launch of its pioneering social media platform, ImpactWayv™ , which is now available to download on the Apple App Store. The new platform’s focus is to connect people, businesses and philanthropy for social good.

Designed to be a healthier and more meaningful alternative to major social networking platforms, ImpactWayv was created to drive collective impact across causes and communities. The platform operates as an entirely new kind of digital ecosystem, enabling users to effect, engage in and share social impact on a global scale.

Users of ImpactWayv will be able to connect and interact with each other through each of its core components, including:

  • Public and private personal networks and content feeds to engage with and create impact.
  • The “Impact Market” – a public exchange of transparent impact profiles of businesses and nonprofits for all to compare, follow, engage with and directly support.
  • “Wayvs” (social impact causes, topics, trends and broader issue areas) – an organizing framework for purpose-driven content and information across the platform.

“ImpactWayv is democratizing social impact for all,” said Dan Rubino, Co-Founder, Chairman and Chief Executive Officer of ImpactWayv, Inc. “Finally, there is a purpose-built social media platform that gives consumers, brands, businesses and nonprofits a way to explore, create, engage and transact across all categories of daily life, with more meaning, more purpose and more goodwill.”

Engagement on the platform is driven by dozens of Wayvs™ ranging across social impact cause areas and covering various topics relating to the interplay of business, philanthropy and individual effort to drive social good. Some examples include Climate Action; Diversity, Equity and Inclusion (DE&I); Corporate Social Responsibility (CSR); Human Rights; Public Health; Environmental, Social and Governance (ESG); Voter Registration; and Renewable Energy. Wayvs facilitate and encourage user discoverability and engagement across the platform. Users tap them to find relevant impact discussions and initiatives, as well as like-minded individuals, companies and nonprofits that share their commitment to the causes they care about.

“An unprecedented interest in social action has been building globally for some time, further accelerated and focused by recent events,” said George Dolatly, Co-Founder and President of ImpactWayv, Inc. “People need a way to explore and express their values. Businesses need to use their resources and influence to make things better. And nonprofits need to leverage their missions for maximum effectiveness. ImpactWayv meets this unique moment in time by linking people and organizations around the world on a deeper level.”

To catalyze user engagement, ImpactWayv also created a groundbreaking tool to measure a user’s impact on their digital community, through the platform’s signature “Impact” metric, which tracks a user’s positive “ripple effect” across the platform, in real time.

“Our ambition at ImpactWayv is to disrupt and transform the worlds of business and philanthropy through technology,” said Benji Bernstein, Co-Founder and Chief Technology Officer of ImpactWayv, Inc. “Through our extraordinary blend of seasoned leaders and trailblazers in the worlds of corporate purpose, philanthropy and technology, we believe we have created a powerful business model that will advance universal social good.”

ImpactWayv is now available for free download on the Apple App Store and will be available on Google Play and other non-iOS devices later this year. Companies and nonprofits are also invited to contact ImpactWayv to become a member of the platform, which will enable them to claim their profile, initiate an engagement strategy on ImpactWayv and become a “Featured Organization” on the platform.

About ImpactWayv, Inc.
ImpactWayv, Inc. is a social impact media and technology company, consisting of thought leaders and doers from across the business, nonprofit and technology sectors. ImpactWayv was created to disrupt and transform the worlds of business and philanthropy through technology – to advance universal social good. For more information, please visit: www.impactwayv.com .

Link:

ClickThru

Social Media:

https://www.facebook.com/impactwayv/

About Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Galderma Receives U.S. FDA Approval for Differin® Epiduo® Acne Gel Prescription-to-OTC Switch22.5.2026 18:25:00 CEST | Press release

A unique Prescription-to-OTC switch in acne care, this approval expands access to a dermatologist-trusted, prescription-strength treatment for millions of acne sufferers ages 12 years and older Backed by more than 15 years of real-world dermatologist use and a robust clinical research program, this milestone demonstrates the depth of science behind the Differin® and Epiduo® heritage Adapalene plus benzoyl peroxide (0.1/2.5%) was the first FDA-approved, stable, fixed- dose prescription acne treatment to combine of benzoyl peroxide with a retinoid, and is now available over-the-counter The formulation is engineered to target multiple causes of acne more effectively than either of its individual active ingredients alone Galderma (SIX: GALD), the pure-play dermatology category leader, today announced that the United States (U.S.) Food and Drug Administration (FDA) has approved Differin® Epiduo® Acne Gel (Adapalene 0.1% and Benzoyl Peroxide 2.5% Acne Treatment) for over-the-counter (OTC) us

Avanzanite Bioscience’s Partner Agios Announces PYRUKYND® (mitapivat) Approval in the European Union for Adults with Thalassaemia22.5.2026 16:18:00 CEST | Press release

Avanzanite will commercialise and distribute PYRUKYND in Europe under its exclusive agreement with Agios Avanzanite is committed to collaborating with local authorities in the EU to enable access to PYRUKYND for adult patients with thalassaemia Avanzanite Bioscience B.V., a rapidly growing commercial-stage European specialty pharmaceutical company focused on rare diseases, today reported that its partner, Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a commercial-stage biopharmaceutical company headquartered in Cambridge, Massachusetts focused on delivering innovative medicines for patients with rare diseases, announced that the European Commission has granted marketing authorisation for PYRUKYND® (mitapivat), an oral pyruvate kinase (PK) activator, in adults for the treatment of anaemia associated with transfusion-dependent and non-transfusion-dependent alpha- or beta-thalassaemia, with an orphan medicinal product designation. This press release features multimedia. View the full releas

ICE Brent and ICE WTI Perpetual Futures to Launch on OKX22.5.2026 14:30:00 CEST | Press release

OKX, a blockchain technology and trading company serving more than 120 million customers globally,and Intercontinental Exchange (NYSE: ICE), one of the world's leading providers of financial market technology and data powering global capital markets including the New York Stock Exchange, today announced plans for OKX to launch perpetual futures based on ICE's Brent Crude and WTI Crude energy benchmarks. The products are expected to be available to trade on OKX’s platform in jurisdictions where OKX is licensed to offer perpetual futures products. The new OKX contracts represent a major step forward in expanding regulated access to global commodity markets through digital asset infrastructure. This first product collaboration between OKX and ICE comes after the companies established a strategic relationship in March 2026. ICE operates some of the world’s leading exchanges, clearing houses and market data services across energy, commodities, fixed income and equities markets. ICE’s future

Enhertu® Recommended for Approval in the EU by CHMP for Patients with Previously Treated HER2 Positive Metastatic Solid Tumors22.5.2026 14:00:00 CEST | Press release

Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the treatment of adult patients with unresectable or metastatic HER2 positive (immunohistochemistry [IHC] 3+) solid tumors who have received prior treatment and who have no satisfactory treatment options. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from patients with HER2 positive (IHC 3+) tumors in three phase 2 trials including DESTINY-PanTumor02,DESTINY-Lung01 andDESTINY-CRC02 where Enhertu demonstrated clinically meaningful responses across a broad range of tumors. The recommendation will now be reviewed by the European Commission, which has the authority

Future Health Challenge Awards USD 300,000 to Early Detection and Population Health Sensing Tools on Sidelines of World Health Assembly22.5.2026 13:45:00 CEST | Press release

Global teams recognised in the Future Health Challenge for solutions designed to detect health risks earlier and support faster health system decisions Future Health – A Global Initiative by Abu Dhabi and MIT Solve announce the winners of the inaugural Future Health ChallengeWinning solution equips frontline health workers in low-resource settings with mobile clinical decision-support tools, enabling earlier detection and more effective care deliveryTeams competed for a USD 200,000 grand prize and two USD 50,000 runner-up awards on the sidelines of the 79th World Health Assembly in GenevaWinners recognised for solutions advancing anticipatory, data-driven health systems Three global teams developing early detection and real-time population health monitoring solutions have secured a total of USD 300,000 on the sidelines of the 79th World Health Assembly. The winning solutions address critical challenges in early detection, continuous population insight and more timely decision making, s

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye